Lecturer on Law
Nisa Leung is a Managing Partner of Qiming Venture Partners and leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages five USD funds and four RMB funds with over USD 2.7 billion in assets and investment in over 160 companies. Nisa is a proven business leader with strong operational experience and successful investment track record.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.
Nisa currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab, Novast Pharmaceuticals, Nurotron Biotechnology, Venus Medtech, Goodwill Infotech, CanSino Biotechnology and Berry Genomics. Nisa oversees Qiming’s investment in CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), OriGene Technologies, Shenogen, Crown Bioscience, Richen, Aeonmed, VR Medical Group, Wuxi Leiming and ACEA Biosciences.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently founding Vice Chair of PhIRDA (China Pharmaceutical Innovation and Research Development Association) Innovation Drug Investment Committee, convener of Venture Investors Alliance of Hong Kong, advisor of Our Hong Kong Foundation, director of Young Entrepreneur Development Council, director of Hong Kong Science and Technology Parks Corporation, council member of HKUST Business School and serves on the Board of Governors of the Hotchkiss School.